Sphingosine-1-phosphate receptor 1/5 selective agonist alleviates ocular vascular pathologies

• Published in: Scientific Reports Vol. 14; no. 1; pp. 9700 - 14
• Main Authors: Nakamura, Shinsuke, Yamamoto, Rie, Matsuda, Takaya, Yasuda, Hiroto, Nishinaka, Anri, Takahashi, Kei, Inoue, Yuki, Kuromitsu, Sadao, Shimazawa, Masamitsu, Goto, Masahide, Narumiya, Shuh, Hara, Hideaki
• Format: Journal Article
• Language: English
• Published: London Springer Science and Business Media LLC 27.04.2024; Nature Publishing Group UK; Nature Publishing Group; Nature Portfolio
• Subjects: 631/154/436; 631/154/436/2387; 631/443/1338/16; Age; Agonists; Angiogenesis; Animal models; Animals; Cell proliferation; Cell Proliferation - drug effects; Choroidal Neovascularization - drug therapy; Choroidal Neovascularization - metabolism; Choroidal Neovascularization - pathology; Disease Models, Animal; Edema; Endothelial cells; Endothelial Cells - drug effects; Endothelial Cells - metabolism; Eye; Eye diseases; Glial cells; Humanities and Social Sciences; Humans; Irradiation; Laser radiation; Localization; Macular degeneration; Male; Medicine; Mice; Mice, Inbred C57BL; Microvasculature; Mueller cells; multidisciplinary; Oral administration; Pathology; Permeability; Q; R; Receptors, Lysosphingolipid - agonists; Receptors, Lysosphingolipid - metabolism; Retina; Science; Science (multidisciplinary); Sphingosine 1-phosphate; Sphingosine-1-Phosphate Receptors - agonists; Sphingosine-1-Phosphate Receptors - metabolism; Vascular endothelial growth factor; Vascular Endothelial Growth Factor A - metabolism; Vascularization
• ISSN: 2045-2322; 2045-2322
• DOI: 10.1038/s41598-024-60540-6

Ocular abnormal angiogenesis and edema are featured in several ocular diseases. S1P signaling via S1P1 likely is part of the negative feedback mechanism necessary to maintain vascular health. In this study, we conducted pharmacological experiments to determine whether ASP4058, a sphingosine 1-phosphate receptor 1/5 (S1P1/5) agonist, is useful in abnormal vascular pathology in the eye. First, human retinal microvascular endothelial cells (HRMECs) were examined using vascular endothelial growth factor (VEGF)-induced cell proliferation and hyperpermeability. ASP4058 showed high affinity and inhibited VEGF-induced proliferation and hyperpermeability of HRMECs. Furthermore, S1P1 expression and localization changes were examined in the murine laser-induced choroidal neovascularization (CNV) model, a mouse model of exudative age-related macular degeneration, and the efficacy of ASP4058 was verified. In the CNV model mice, S1P1 tended to decrease in expression immediately after laser irradiation and colocalized with endothelial cells and Müller glial cells. Oral administration of ASP4058 also suppressed vascular hyperpermeability and CNV, and the effect was comparable to that of the intravitreal administration of aflibercept, an anti-VEGF drug. Next, efficacy was also examined in a retinal vein occlusion (RVO) model in which retinal vascular permeability was increased. ASP4058 dose-dependently suppressed the intraretinal edema. In addition, it suppressed the expansion of the perfusion area observed in the RVO model. ASP4058 also suppressed the production of VEGF in the eye. Collectively, ASP4058 can be a potential therapeutic agent that normalizes abnormal vascular pathology, such as age-related macular degeneration and RVO, through its direct action on endothelial cells.